1887

Abstract

Seneca Valley virus (SVV-001) is an oncolytic picornavirus with selective tropism for a subset of human cancers with neuroendocrine differentiation. To characterize further the specificity of SVV-001 and its patterns and kinetics of intratumoral spread, bacterial plasmids encoding a cDNA clone of the full-length wild-type virus and a derivative virus expressing GFP were generated. The full-length cDNA of the SVV-001 RNA genome was cloned into a bacterial plasmid under the control of the T7 core promoter sequence to create an infectious cDNA clone, pNTX-09. A GFP reporter virus cDNA clone, pNTX-11, was then generated by cloning a fusion protein of GFP and the 2A protein from foot-and-mouth disease virus immediately following the native SVV-001 2A sequence. Recombinant GFP-expressing reporter virus, SVV–GFP, was rescued from cells transfected with RNA transcripts from pNTX-11 and propagated in cell culture. The proliferation kinetics of SVV-001 and SVV–GFP were indistinguishable. The SVV–GFP reporter virus was used to determine that a subpopulation of permissive cells is present in small-cell lung cancer cell lines previously thought to lack permissivity to SVV-001. Finally, it was shown that SVV–GFP administered to tumour-bearing animals homes in to and infects tumours whilst having no detectable tropism for normal mouse tissues at 1×10 viral particles kg, a dose equivalent to that administered in ongoing clinical trials. These infectious clones will be of substantial value in further characterizing the biology of this virus and as a backbone for the generation of additional oncolytic derivatives.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.046011-0
2012-12-01
2019-10-20
Loading full text...

Full text loading...

/deliver/fulltext/jgv/93/12/2606.html?itemId=/content/journal/jgv/10.1099/vir.0.046011-0&mimeType=html&fmt=ahah

References

  1. de Felipe P., Martín V., Cortés M. L., Ryan M., Izquierdo M.. ( 1999;). Use of the 2A sequence from foot-and-mouth disease virus in the generation of retroviral vectors for gene therapy. . Gene Ther 6:, 198–208. [CrossRef][PubMed]
    [Google Scholar]
  2. de Felipe P., Hughes L. E., Ryan M. D., Brown J. D.. ( 2003;). Co-translational, intraribosomal cleavage of polypeptides by the foot-and-mouth disease virus 2A peptide. . J Biol Chem 278:, 11441–11448. [CrossRef][PubMed]
    [Google Scholar]
  3. Donnelly M. L., Gani D., Flint M., Monaghan S., Ryan M. D.. ( 1997;). The cleavage activities of aphthovirus and cardiovirus 2A proteins. . J Gen Virol 78:, 13–21.[PubMed]
    [Google Scholar]
  4. Donnelly M. L., Hughes L. E., Luke G., Mendoza H., ten Dam E., Gani D., Ryan M. D.. ( 2001a;). The ‘cleavage’ activities of foot-and-mouth disease virus 2A site-directed mutants and naturally occurring ‘2A-like’ sequences. . J Gen Virol 82:, 1027–1041.[PubMed]
    [Google Scholar]
  5. Donnelly M. L., Luke G., Mehrotra A., Li X., Hughes L. E., Gani D., Ryan M. D.. ( 2001b;). Analysis of the aphthovirus 2A/2B polyprotein ‘cleavage’ mechanism indicates not a proteolytic reaction, but a novel translational effect: a putative ribosomal ‘skip’. . J Gen Virol 82:, 1013–1025.[PubMed]
    [Google Scholar]
  6. Funston G. M., Kallioinen S. E., de Felipe P., Ryan M. D., Iggo R. D.. ( 2008;). Expression of heterologous genes in oncolytic adenoviruses using picornaviral 2A sequences that trigger ribosome skipping. . J Gen Virol 89:, 389–396. [CrossRef][PubMed]
    [Google Scholar]
  7. Gerlinger M., Rowan A. J., Horswell S., Larkin J., Endesfelder D., Gronroos E., Martinez P., Matthews N., Stewart A.. & other authors ( 2012;). Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. . N Engl J Med 366:, 883–892. [CrossRef][PubMed]
    [Google Scholar]
  8. Hales L. M., Knowles N. J., Reddy P. S., Xu L., Hay C., Hallenbeck P. L.. ( 2008;). Complete genome sequence analysis of Seneca Valley virus-001, a novel oncolytic picornavirus. . J Gen Virol 89:, 1265–1275. [CrossRef][PubMed]
    [Google Scholar]
  9. Ibrahimi A., Vande Velde G., Reumers V., Toelen J., Thiry I., Vandeputte C., Vets S., Deroose C., Bormans G.. & other authors ( 2009;). Highly efficient multicistronic lentiviral vectors with peptide 2A sequences. . Hum Gene Ther 20:, 845–860. [CrossRef][PubMed]
    [Google Scholar]
  10. Kaplan G., Lubinski J., Dasgupta A., Racaniello V. R.. ( 1985;). In vitro synthesis of infectious poliovirus RNA. . Proc Natl Acad Sci U S A 82:, 8424–8428. [CrossRef][PubMed]
    [Google Scholar]
  11. Luke G. A., de Felipe P., Lukashev A., Kallioinen S. E., Bruno E. A., Ryan M. D.. ( 2008;). Occurrence, function and evolutionary origins of ‘2A-like’ sequences in virus genomes. . J Gen Virol 89:, 1036–1042. [CrossRef][PubMed]
    [Google Scholar]
  12. Morton C. L., Houghton P. J., Kolb E. A., Gorlick R., Reynolds C. P., Kang M. H., Maris J. M., Keir S. T., Wu J., Smith M. A.. ( 2010;). Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program. . Pediatr Blood Cancer 55:, 295–303. [CrossRef][PubMed]
    [Google Scholar]
  13. Osborn M. J., Panoskaltsis-Mortari A., McElmurry R. T., Bell S. K., Vignali D. A., Ryan M. D., Wilber A. C., McIvor R. S., Tolar J., Blazar B. R.. ( 2005;). A picornaviral 2A-like sequence-based tricistronic vector allowing for high-level therapeutic gene expression coupled to a dual-reporter system. . Mol Ther 12:, 569–574. [CrossRef][PubMed]
    [Google Scholar]
  14. Porterfield J. Z., Zlotnick A.. ( 2010;). A simple and general method for determining the protein and nucleic acid content of viruses by UV absorbance. . Virology 407:, 281–288. [CrossRef][PubMed]
    [Google Scholar]
  15. Racaniello V. R., Baltimore D.. ( 1981;). Cloned poliovirus complementary DNA is infectious in mammalian cells. . Science 214:, 916–919. [CrossRef][PubMed]
    [Google Scholar]
  16. Reddy P. S., Burroughs K. D., Hales L. M., Ganesh S., Jones B. H., Idamakanti N., Hay C., Li S. S., Skele K. L.. & other authors ( 2007;). Seneca Valley virus, a systemically deliverable oncolytic picornavirus, and the treatment of neuroendocrine cancers. . J Natl Cancer Inst 99:, 1623–1633. [CrossRef][PubMed]
    [Google Scholar]
  17. Rudin C. M., Poirier J. T., Senzer N. N., Stephenson J. Jr, Loesch D., Burroughs K. D., Reddy P. S., Hann C. L., Hallenbeck P. L.. ( 2011;). Phase I clinical study of Seneca Valley Virus (SVV-001), a replication-competent picornavirus, in advanced solid tumors with neuroendocrine features. . Clin Cancer Res 17:, 888–895. [CrossRef][PubMed]
    [Google Scholar]
  18. Ryan M. D., Drew J.. ( 1994;). Foot-and-mouth disease virus 2A oligopeptide mediated cleavage of an artificial polyprotein. . EMBO J 13:, 928–933.[PubMed]
    [Google Scholar]
  19. Ryan M. D., Donnelly M., Lewis A., Mehrotra A. P., Wilkie J., Gani D.. ( 1999;). A model for nonstoichiometric, cotranslational protein scission in eukaryotic ribosomes. . Bioorg Chem 27:, 55–79. [CrossRef]
    [Google Scholar]
  20. Szymczak A. L., Workman C. J., Wang Y., Vignali K. M., Dilioglou S., Vanin E. F., Vignali D. A.. ( 2004;). Correction of multi-gene deficiency in vivo using a single ‘self-cleaving’ 2A peptide-based retroviral vector. . Nat Biotechnol 22:, 589–594. [CrossRef][PubMed]
    [Google Scholar]
  21. Teterina N. L., Levenson E. A., Ehrenfeld E.. ( 2010;). Viable polioviruses that encode 2A proteins with fluorescent protein tags. . J Virol 84:, 1477–1488. [CrossRef][PubMed]
    [Google Scholar]
  22. van der Werf S., Bradley J., Wimmer E., Studier F. W., Dunn J. J.. ( 1986;). Synthesis of infectious poliovirus RNA by purified T7 RNA polymerase. . Proc Natl Acad Sci U S A 83:, 2330–2334. [CrossRef][PubMed]
    [Google Scholar]
  23. Wadhwa L., Hurwitz M. Y., Chévez-Barrios P., Hurwitz R. L.. ( 2007;). Treatment of invasive retinoblastoma in a murine model using an oncolytic picornavirus. . Cancer Res 67:, 10653–10656. [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.046011-0
Loading
/content/journal/jgv/10.1099/vir.0.046011-0
Loading

Data & Media loading...

Supplements

Supplementary material 

PDF

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error